Patents by Inventor John Trauger

John Trauger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE
    Publication number: 20220213181
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Inventors: Regis CEBE, Igor SPLAWSKI, John TRAUGER, Andrei Igorevich VOZNESENSKY
  • ANTIBODY CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION
    Publication number: 20220127321
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Application
    Filed: August 26, 2021
    Publication date: April 28, 2022
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • LPL-GPIHBP1 FUSION POLYPEPTIDES
    Publication number: 20220025344
    Abstract: This disclosure relates to fusion polypeptides comprising lipoprotein lipase (LPL) and glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding protein 1 (GPIHBP1). The disclosure also relates to uses of such fusion polypeptides in treating disease such as familial chylomicronemia syndrome (FCS).
    Type: Application
    Filed: November 25, 2019
    Publication date: January 27, 2022
    Inventors: Jiaping GAO, Amitabh NIMONKAR, John TRAUGER, Andrei Igorevich VOZNESENSKY, Stephen Craig WELDON
  • Methods of treating immune related disorders using antibody-cytokine engrafted compositions
    Patent number: 11136366
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 10870698
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 22, 2020
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE
    Publication number: 20200392215
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: January 23, 2020
    Publication date: December 17, 2020
    Inventors: John TRAUGER, Andrei Igorevich VOZNESENSKY
  • Angiopoietin-like 4 antibodies and methods of use
    Patent number: 10577411
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: March 3, 2020
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky
  • ANTIBODY-CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION
    Publication number: 20190241636
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Application
    Filed: October 18, 2018
    Publication date: August 8, 2019
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190040128
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 7, 2019
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Antibody cytokine engrafted compositions and methods of use for immunoregulation
    Patent number: 10144768
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 4, 2018
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
    Patent number: 9988443
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky, Julia Neugebauer, Steffen Runz
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9988455
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9982046
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 29, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE
    Publication number: 20180044410
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: August 25, 2017
    Publication date: February 15, 2018
    Applicant: Novartis AG
    Inventors: John TRAUGER, Andrei Igorevich VOZNESENSKY
  • Angiopoietin-like 4 antibodies and methods of use
    Patent number: 9771417
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 26, 2017
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170260272
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: December 23, 2016
    Publication date: September 14, 2017
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Jennifer BROGDON, William DOLE, John TRAUGER, Yuting TANG, Julia NEUGEBAUER, Annika SCHMID
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170152313
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 1, 2017
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9562101
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: February 7, 2017
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9512222
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 6, 2016
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE
    Publication number: 20160145326
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: August 6, 2015
    Publication date: May 26, 2016
    Applicant: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky